Trexquant Investment’s DiaMedica Therapeutics DMAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$151K Sell
22,261
-8,693
-28% -$68.9K ﹤0.01% 1683
2025
Q4
$246K Buy
+30,954
New +$231K ﹤0.01% 1488
2021
Q3
Sell
-17,019
Closed -$76K 1213
2021
Q2
$76K Buy
+17,019
New +$140K 0.01% 1033

Other funds holding DMAC

Trexquant Investment's DMAC Position: Q1 2026 in Review

Trexquant Investment reduced its DiaMedica Therapeutics (DMAC) stake by 28% in Q1 2026, selling an estimated $68.9K and leaving 22,261 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

Trexquant Investment first reported a position in DMAC in Q2 2021 and has held it in 3 quarters since. The position peaked at $246K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Trexquant Investment held 22,261 shares of DiaMedica Therapeutics worth $151K as of Q1 2026.
  • Trexquant Investment sold 8,693 DiaMedica Therapeutics shares in Q1 2026, an estimated $68.9K.
  • DiaMedica Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q1 2026, its #1683 holding.
  • Trexquant Investment first reported a position in DiaMedica Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Trexquant Investment's DiaMedica Therapeutics position peaked at $246K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.